Cost of Failure, Disruptive Innovation and Targeted Flexicurity: More Evidence Supporting Targeted Reforms
In the European Union, high restructuring costs due to Employment Protection Laws, combined with the high level of failure characteristic of disruptive innovation, make investment in tech and biotech essentially unprofitable.